University College of London collaboration: DBDNA™ for gene therapy
Touchlight has entered into collaboration with Professor Simon Waddington’s group at the Institute for Women’s Health at UCL. The collaboration aims to investigate the potential to generate conventional gene therapy viral vectors (specifically lentivirus and adeno-associated virus) using doggybones™ in a triple transfection system
- ENDS -
Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
|Karen Fallen, Chief Executive Officer||Instinctif|
|Robin Bodicoat, Head of Marketing||E: email@example.com|
|E: firstname.lastname@example.org||T: +44 20 7457 2020|
|T: +44 20 8481 9200|